Usefulness of urine dipstick test in the management of adverse events associated with immune checkpoint inhibitors

被引:0
|
作者
Izumi, Keishiro [1 ]
Iyoda, Tomokazu [1 ,2 ]
Yokota, Atsuko [3 ]
Kanno, Masahito [2 ]
Hoshi, Masahiro [2 ]
Tokuda, Emi [4 ]
Sasaki, Eisaku [4 ]
Kanazawa, Kenya [1 ]
Kuroda, Junko [2 ]
Saji, Shigehira [1 ,4 ]
机构
[1] Fukushima Med Univ Hosp, Clin Oncol Ctr, 1 Hikarigaoka, Fukushima, Fukushima, Japan
[2] Fukushima Med Univ Hosp, Dept Pharm, 1 Hikarigaoka, Fukushima, Fukushima, Japan
[3] Tochigi Canc Ctr, Dept Pharm, 4-9-13 Yonan, Utsunomiya, Tochigi, Japan
[4] Fukushima Med Univ, Dept Med Oncol, 1 Hikarigaoka, Fukushima, Fukushima, Japan
关键词
Immune checkpoint inhibitor; Urine dipstick test; Patient's diary; Telephone follow-up; Pharmacist; THERAPY MANAGEMENT; URINALYSIS; DIARY;
D O I
10.1007/s00520-024-08928-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe usefulness of urine dipstick tests (UDTs) in patients with diabetes has been reported. The aim of the present study was to investigate the utility of self-performed UDTs and patient diaries in the management of impaired glucose tolerance, one of the adverse events of immune checkpoint inhibitors (ICIs).MethodsPatients receiving ICIs underwent self-checks with UDTs twice a week for up to 6 months. Pharmacists checked the results at every patient visit, and by phone every 3 months. The primary endpoint was to prospectively assess whether symptoms recorded in patient diaries and UDTs could reduce unscheduled hospital admissions due to impaired glucose tolerance. The secondary endpoint was the correlation between the symptoms in the patient diaries and UDT results.ResultsA total of 112 patients were enrolled in the study. Out of the 3197 planned self-UDTs, 3128 (97.8%) were performed. Forty-four patients (39.3%) were admitted to the hospital, two (1.8%) of whom were admitted due to abnormal glucose tolerance, with one having a positive UDT. There were 46 unscheduled outpatient visits (41.1%), of which five (4.5%) were due to abnormal glucose tolerance symptoms and four were due to a positive UDT. The correlation between descriptions of fatigue or dry mouth in the patient diaries and positive glucose UDTs was 52.4% in sensitivity and 62.4% in specificity.ConclusionSelf-monitoring of symptoms and self-performing of UDTs could not reduce the emergency hospitalization rate. However, this approach could be effective in the objective monitoring of patient status, especially regarding glucose intolerance occurrences.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma: A nursing perspective
    Thebeau, Melissa
    Rubin, Krista
    Hofmann, Matthias
    Grimm, Julia
    Weinstein, Alyona
    Choi, Jennifer N.
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2017, 29 (05) : 294 - 303
  • [22] Checkpoint Inhibitors Common immune-related adverse events and their management
    Gordon, RuthAnn
    Kasler, Mary Kate
    Stasi, Kristen
    Shames, Yelena
    Errante, Mimma
    Ciccolini, Kathryn
    Lucas, Anna Skripnik
    Raasch, Pam
    Fischer-Cartlidge, Erica
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2017, 21 (02) : 45 - 52
  • [23] Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
    Zheng-Hang Wang
    Lin Shen
    慢性疾病与转化医学(英文), 2018, 4 (01) : 1 - 7
  • [24] Peripheral nervous system adverse events associated with immune checkpoint inhibitors
    Rossi, Simone
    Gelsomino, Francesco
    Rinaldi, Rita
    Muccioli, Lorenzo
    Comito, Francesca
    Di Federico, Alessandro
    De Giglio, Andrea
    Lamberti, Giuseppe
    Andrini, Elisa
    Mollica, Veronica
    D'Angelo, Roberto
    Baccari, Flavia
    Zenesini, Corrado
    Madia, Pierandrea
    Raschi, Emanuel
    Cortelli, Pietro
    Ardizzoni, Andrea
    Guarino, Maria
    JOURNAL OF NEUROLOGY, 2023, 270 (06) : 2975 - 2986
  • [25] Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews
    Kanji, Salmaan
    Morin, Sydney
    Agtarap, Kyla
    Purkayastha, Debanjali
    Thabet, Pierre
    Bosse, Dominick
    Wang, Xiang
    Lunny, Carole
    Hutton, Brian
    DRUGS, 2022, 82 (07) : 793 - 809
  • [26] Common endocrine system adverse events associated with immune checkpoint inhibitors☆
    Li, Ying
    Zhao, Junfeng
    Wang, Yue
    Xu, Yali
    Li, Ruyue
    Zhao, Ying
    Dong, Xue
    Yao, Xiujing
    Li, Yintao
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (03): : 164 - 172
  • [27] Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews
    Salmaan Kanji
    Sydney Morin
    Kyla Agtarap
    Debanjali Purkayastha
    Pierre Thabet
    Dominick Bosse
    Xiang Wang
    Carole Lunny
    Brian Hutton
    Drugs, 2022, 82 : 793 - 809
  • [28] Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
    Cuzzubbo, S.
    Javeri, F.
    Tissier, M.
    Roumi, A.
    Barlog, C.
    Doridam, J.
    Lebbe, C.
    Belin, C.
    Ursu, R.
    Carpentier, A. F.
    EUROPEAN JOURNAL OF CANCER, 2017, 73 : 1 - 8
  • [29] Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
    A. Martens
    P. P. Schauwvlieghe
    A. Madoe
    I. Casteels
    S. Aspeslagh
    Journal of Ophthalmic Inflammation and Infection, 13
  • [30] PERIPHERAL NERVOUS SYSTEM ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS
    Rossi, S.
    Gelsomino, F.
    Rinaldi, R.
    Muccioli, L.
    Comito, F.
    Lamberti, G.
    D'Angelo, R.
    Raschi, E.
    Ardizzoni, A.
    Cortelli, P.
    Guarino, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 602 - 603